Patients with cystic fibrosis (CF) may be more susceptible to oxidative cell injury than normal healthy children due to both the impaired absorption of antioxidant nutrients and the increased oxidative stress caused by chronic pulmonary infections. The purpose of this study was to examine whether markers of oxidative damage to lipids (malondialdehyde-like substances and lipid hydroperoxides) and proteins (protein carbonyls) were present in the plasma of CF patients. Mean values (? SD) of thiobarbituric acid-reactive substances were significantly higher in patients (6.93 & 1.47 prnol/L, n = 25) than in controls (5.84 2 0.59 ~mol/L,; n = 10). FFA hydroperoxides were not detected in control subjects (the detection limit of the assay was 0.02 pmol/L), but in 11 of the 33 CF patients studied they were found in a range of 0.03-0.34 pmoVL. Plasma protein carbonyl concentrations did not differ significantly between the two groups @ = 0.076), although a much wider distribution was observed in the CF patients (range 0.17-5.64 nmollmg protein) than in the control group (range 0.24-1.55 nmollmg protein). No correlation was found between thiobarbituric acid-reactive substances and FFA
hydroperoxides or between either of these markers and protein carbonyl content. Concentrations of plasma vitamin E, vitamin C, and protein sulfhydryls were within the normal ranges in both control subjects and CF patients. The concentration of uric acid was significantly reduced @ < 0.01) in the CF group (204 2 96.99 pmoI/L) compared with that in control subjects (352 2 81.11 pmol/L), but reduction in plasma levels of this antioxidant did not correlate with increased markers of free radical damage. These results indicate that certain CF patients are more susceptible to oxidative damage, even in the presence of relatively normal concentrations of the major plasma antioxidants; these patients may benefit from increased antioxidant consumption. A variety of studies have shown that the immune response in patients with C F is increased (8, 9) , and analysis of bronchoalveolar lavage fluid has revealed a 1000-fold increase in the number of neutrophils recovered from the lungs compared with controls (10) . Because it is well established that neutrophils, when activated, are a major source of free radicals (ll), it follows that those CF patients with marginal or depleted antioxidant defenses are likely to exhibit evidence of increased oxidative stress, especially during episodes of acute pulmonary infection. Results from our previous study (6) support such a hypothesis; we found that C F plasma had a reduced capacity to withstand increased oxidative damage in vitro, indicating that patients may be more sensitive to free radical-mediated attack in vivo.
The purpose of the present study was to examine the hypothesis that patients with CF are more susceptible to 488 BROWN AP JD KELLY free radical-induced oxidative injury than healthy agematched controls. We investigated two sensitive markers of lipid peroxidation (TBA-reactive substances and FFA hydroperoxides) and one marker of protein oxidation (protein carbonyls), using stringent precautions to prevent the loss of these labile markers or their spurious production during the preparation and analysis of the samples.
METHODS

Chemicak.
All chemicals used were obtained from Sigma (Poole, England) and HPLC-grade solvents were obtained from Rathburn Chemicals (Winterburn, Scotland). 15(S)hydroperoxyeicosatetraenoic acid standard was obtained from Cascade Bioactive Lipids (Reading, England).
Subjects. Venous blood samples were collected from both control subjects and patients with CF. Patients were attending the C F clinic at Southampton General Hospital, for a regular (6 monthly) checkup and did not present with specific problems. The mean age of the CF group was 10 y, 3 mo (n = 45, range = 2 y, 11 mo to 18 y). The control group comprised patients attending St Thomas' Hospital Ear, Nose, and Throat Department for blood tests before tonsillectomy; they had a mean age of 7 y, 11 mo (n = 11, range = 2 y, 4 mo to 21 y, 4 mo). Ethical permission for this study was obtained from the Joint Ethical Subcommittee, Southampton and South West Hampshire Health Authority, for the C F patients and from the West Lambeth Health Authority Ethics Committee for the control subjects.
Sample lurnding. Blood (4 mL) was collected from C F patients and controls and immediately divided equally between two heparinized tubes on ice, one of which contained 20 p L of 2 mmol/L butylated hydroxytoluene and 20 p L of 2 mmol/L Desferal (Sigma Chemical Co., Poole, Dorset, UK). The blood was then centrifuged at 1500 rpm at 4°C for 10 min and the plasma stored at -80°C for up to 4 wk before being analyzed. Plasma samples protected with butylated hydroxytoluene and Desferal were used to determine the concentration of oxidative markers, whereas those without additional antioxidants were used to determine individual antioxidant concentrations. All variables measured were found to be stable under the conditions of storage.
Determination of a-tocopherol. Aliquots of 100 p L of plasma were extracted with 100 p L of anhydrous HPLCgrade ethanol and 400 p L of HPLC-grade hexane. &-Tocopherol acetate was added as an internal standard. The hexane layer was removed and evaporated to dryness under a stream of nitrogen. The extract was then redissolved in 400 FL of HPLC-grade methanol, and 100-pL aliquots were analyzed by HPLC. A 7 x 100-mm, 5-p,m C18 column (Jones Chromatography, Hengoed, Wales, UK) was eluted with methano1:water (39:l vol/vol), at a flow rate of 0.8 mumin. Detection was by absorbance at 292 nm (12) .
Determination of ascorbic acid and uric acid. The HPLC determination of uric acid and ascorbate was based on the method of Iriyama et a1 (13) . Plasma (100 pL) was extracted with 400 p L of 2% metaphosphoric acid and 100 p L of HPLC-grade heptane. Samples were vortex mixed for 40 s and then centrifuged at 13 000 x g for 5 min. Aliquots of 20 p L were injected for analysis using a Gilson model 231 autosampler (Gilson Medical Electronics, France). A 10 x 300-mm, 5-pm C18 column was eluted with a 0.2 mol/L K,HP04-H,P04 running buffer, pH 2.1, containing 0.25 mmol/L octanesulfonic acid at a flow rate of 1.8 mumin. An EG & G electrochemical detector (Jones Chromatography) was used for detection, with E (applied potential between the working and reference electrode) set at 810 mV, time constant set at 5 s, cathodic output, and a sensitivity of 100 nA.
Determination of total p h m a sulfiydryls. Plasma sulfhydryls were assayed by the method of Ellman (14) , in which 25 p L of plasma were added to 975 p L of 0.2 mol/L Na2HP04, 2 mmol/L EDTA, pH 9.0, and 20 FL of 53'-dithio-bis(2-nitrobenzoic) acid (10 mmol/L in 0.05 mol/L phosphate buffer, pH 7.0). Absorbance at 412 nm was determined on an LKB Ultraspec I1 spectrophotometer (LKB Biochrom Ltd., Cambridge, UK) against an appropriate blank and the concentration of sulfhydryls calculated using the equation c = A/E x d, where A = absorbance, E = the extinction coefficient (13 600), and d = the path length (1 cm).
TBA determination of lipid h y d r o p e d e s . The method used was an adaptation of the original assay described by Yagi (15) . A tube containing 2.0 mL of 12 N H2S04 and 10 p L of plasma had added to it 0.25 mL of 10% wthol phosphotungstic acid; it was then left to stand at room temperature for 5 min before being spun at 13 000 x g for 10 min at room temperature. The supernatant was discarded and the pellet resuspended in 1.0 mL of 12 N H2S04 and 0.15 mL of 10% vol/vol phosphotungstic acid. The mixture was again centrifuged at 13 000 x g for 10 min at 10°C. The pellet was resuspended in 2.0 mL of water by vigorous mixing, and 0.5 mL of TBA reagent (a mixture of equal volumes of 0.67% TBA aqueous solution and glacial acetic acid) was added and the reaction mixture heated at 9S°C for 60 min in a water bath. After cooling on ice, 2.5 mL of butan-1-01 were added and the mixture was vortexed for 20 s. The final solution was centrifuged again at 13 000 x g for 10 min and the n-butanol layer removed for fluorometric detection at 553 nm with excitation at 515 nm against an appropriate blank. The lipid peroxide concentration was determined by producing a standard curve (range = 0.04-0.125 pmol/L) obtained by reacting different concentrations of tetraethoxypropane with TBA and then treating them in the same way as the plasma samples. All samples were run in duplicate with an intraassay variability of < 10%.
HPLC determination of plasma lipid hydroperoxides. Lipid hydroperoxide extraction from plasma was carried out on ice in glass tubes protected from light. To 0.5 mL of plasma, 0.25 mL of 0.2 molL citric acid was added followed by 6 mL of hexane. The samples were mixed vigorously and centrifuged at 2000 rpm for 5 min at 4°C. The upper layer was removed and dried under a stream of nitrogen while shielded from light. The extract was redissolved in 100 p L of methanol, and 20-pL samples were injected onto a C18 column and eluted with methanol containing 0.02% triethylamine at a flow rate of 1 mumin. The reaction solution, consisting of 1 mmol/L isoluminol in methanol 0.1 molL and sodium borate buffer, pH 10 (30:70, vol/vol), was made up 24 h before use to ensure that the intrinsic chemiluminescence had diminished and so would not affect the results. It was then added to microperoxidase dissolved in 10 mmol/L Tris, pH 7.4, to a final concentration of 1 pg/mL and filtered through a 0.45-pm membrane before use. After passing through the UV detector, the running buffer was mixed with the reaction mixture via a T-joint and incubated in a 15-s mixing coil. The chemiluminescence generated by the presence of hydroperoxides was detected using an Applied Biosystems 980 fluorometric detector (Applied Biosystems, Ramsey, NJ) acting as a photomultiplier at 550 nm with a range setting of 0.001 A. A standard curve of 15(S)hydroperoxyeicosatetraenoic acid (range = 1.83-14.71 pmol/L), which is equivalent to a plasma concentration of 0.02-0.15 pmol/L with the detection limit of the assay being 0.02 pmol/L, was run. All the standards and the samples were run in duplicate, with an intraassay variability of < 10%.
Determination of carbonyl content. The assay used was based on that developed by Levine et a1 (16) . An aliquot of 100 p L of plasma was diluted Zfold in 5 mmolL EDTA, pH 7.4. This sample was then divided into two separate aliquots, precipitated with 500 p L of 20% trichloroacetic acid, and centrifuged at 13 000 x g for 3 min. Both supernatants were discarded; one pellet was redissolved in 2 mol/L HCI containing 0.1% DNP solution and the other, which acted as the blank and was run in parallel, in 2 mol/L HCI alone. The pellets were sonicated at 14 microns (vibration units) for 10 s to aid dissolution. The samples were then left to stand at room temperature for 1 h with vigorous mixing every 15 min; at the end of this period, 500 p L of 20% trichloroacetic acid were added to reprecipitate the protein; the mixture was then centrifuged at 13 000 x g for 3 min. The pellets were washed three times with 1 mL of ethanollethyl acetate (1:l) to remove the free reagent, with the sample allowed to stand for 10 min before centrifugation and the supernatant discarded each time. The final pellet produced from these washings was redissolved in 1 mL of 6 mol/L guanidine-HC1 by warming gently at 37OC for 15 min followed by sonication at 14 microns for 10 s. After a last spin at 13 000 x g for 3 min, the absorbance of each sample and its corresponding blank was read against a blank containing 6 mol/L guanidine-HC1 using an LKB Ultraspec I1 at a wavelength of 370 nm. The carbonyl content was calculated using the equation c = Ale x d, where A = absorbance, E = extinction coefficient (22 000 mol/L-' cm-'), and d = pathlength (1 cm).
The protein concentration was determined by taking 10-p,L samples from the tubes containing the DNP and their parallel blanks and adding 200 p.L of bicinchoninic acid solution (made up of 50 mL of bicinchoninic acid and 1 mL of 4% CuSO, solution), incubating them at 37OC for 30 min, and then measuring the absorbance at 560 nm. The carbonyl content in nmollmg protein of the samples was calculated by subtracting the reading from the parallel blanks, corresponding to a background count, from the tubes containing DNP. All samples were run in duplicate with an intraassay variability of <5%.
Statisticalanalysis. Data are presented as median values with ranges. Statistical analysis was performed using unpaired t test for parametric data. Because no values were obtained from the HPLC determination of lipid hydroperoxides in the control samples (they were below the limit of detection), the data were analyzed using the Fisher Exact test (17) . Table 1 provides a summary of the demographic details of the control subjects and C F patients. Table 2 summarizes the concentrations of the four major antioxidants measured in the plasma of the two groups. Median a-tocopherol concentrations for both groups were within the reported normal range (18) , although a number of C F patients (10 of 33) had plasma vitamin E concentrations below the lower acceptable limit of 10 pmol/L. In addition, a much wider distribution of a-tocopherol concentrations was seen in C F patients, suggesting greater variability in dietary supply, efficiency of absorption of a-tocopherol, or both.
RESULTS
Median plasma vitamin C concentrations were similar in the two groups. In control subjects, plasma vitamin C concentration ranged from 4.13 to 92.03 pmol/L, with two individuals having concentrations below the reported normal range of 11-100 pmol/L. The distribution in the C F group was similar, with concentrations ranging from 23.48 to 94.18 pmol/L. There was, however, an agedependent decrease in plasma vitamin C concentration (r = -0 . 6 ,~ = 0.005) in these patients. No differences with regard to gender were observed in any of the antioxidant concentrations within either group.
Plasma uric acid concentrations were found to be significantly lower in C F patients compared with agematched controls, although the median concentrations for both groups were within the reported normal range of Statistical difference between groups @ < 0.01 or better).
120420 pmoVL (19) . C F patients showed a wider distribution in the plasma urate concentrations, with a range from 81.96 to 380.45 pmollL; four of the 22 patients examined had concentrations at or below the lower end of the normal range. However, no correlation was found between the concentration of uric acid and markers of lipid peroxidation and protein oxidation. Plasma sulfhydry1 concentrations for the CF patients and age-matched control subjects did not differ significantly, but the median values for the two groups (574.50 and 631.40 pmol/L, respectively) were both at the high end of the reported normal range of 353-700 pmoVL (19) . Indices of oxidative stress in age-matched control subjects and CF patients are shown in Figures 1 and 2 . Concentrations of TBA-reactive substances were significantly elevated in the patients with CF (range = 4.77-10.30 pmol1L) compared with age-matched controls (range = 4.92-6.86 pmol/L). There was a much larger distribution of values in the CF population, with a number of patients (11 of 26) having concentrations in the plasma greater than 7 nmol/L (Fig. L4 ). An agedependent increase in TBA-reactive substances was seen in the C F group (r = 0 . 5 4 ,~ = 0.007), a finding that has also been reported in normal populations by yagi (20)- Figure I . Markers of lipid peroxidation in control samples and samples acid h~drO~eroxides, measured HPLC, were from patients with CF showing the individual values within each group also significantly elevated in CF patients compared with and the medians. A, TBA-reactive substances (TBARS) (n = 11 concontrol subjects @ < 0.01). In 11 of the 33 C F patients trols, n = 26 CF patients). B, FFA lipid hydroperoxides (n = 11 studied, concentrations ranged from 0.022 to 0.34 cOntrOIs~n = 33 CFpatients)-pmoVL. In contrast, FFA hydroperoxides were not de---tected in 22 C F patients or in any of the age-matched control plasma samples (Fig. 1B) .
Plasma protein carbonyl concentrations did not differ significantly ( p = 0.076) between the two groups (Fig. 2) . In control subjects, concentrations ranged from 0.21 to 2.24 nmollmg protein and the median concentration was in the reported normal range of e 1 nmollmg protein (21) . The median concentration of protein carbonyls for the C F group was 1.64 nmoVmg protein, but there was a much greater variation in the individual concentrations compared with the controls, with 15 of 28 patients having concentrations above the reported normal value of 1 nmoVmg protein.
infections and an impaired ability to absorb fat-soluble nutrients (22) . Deficiencies of circulating antioxidants, especially vitamin E (23), serum albumin (24) , and ferritin (25) , have been previously reported in CF, and examination of the fluid lining the epithelium in the lung has shown it to be deficient in glutathione (26) . Circulating (and presumably tissue) antioxidants are deficient in CF patients during periods of increased free radical flux, such as during bouts of acute pulmonary infection. Combined, these two events increase the oxidative burden on the lungs of the CF patient with the subsequent production of intermediates of free radical metabolism, which may then enter the circulation. We have addressed the DISCUSSION question of antioxidantlfree radical imbalance for two reasons. First, we believe that circulating free radical C F is characterized by abnormal mucosal secretions, metabolites may represent sensitive markers of oxidative particularly in the lung and gastrointestinal tract, which stress and may thus be useful in detecting those patients result in recurrent and severe bacterial and fungal chest at risk at an early stage of imbalance. Second, because many of the intermediate products of free radical metabolism are reactive in their own right, we believe they may be responsible for injury to other tissues in the body.
At the outset of the study, we decided to investigate the presence of markers of both lipid and protein oxidation. The most widely used method of measuring lipid oxidation involves the determination of malondialdehyde, a breakdown product of lipid peroxidation, by its reaction with TBA to form a colored product (15) . Both control subjects and the C F patients enrolled in the study exhibited evidence of lipid peroxidation with this method. The median concentration of TBA-reactive substances was significantly increased in the CF population due to elevated concentrations in about 40% of the patients studied. The concentration of TBA-reactive substances in this subgroup of CF patients was comparable to that reported in patients with diabetes mellitus (27) and patients with acute hepatic failure (20) . Because the TBA assay is not very specific and there have been concerns about its validity (28) , it should no longer be used as a sole index of lipid peroxidation. For this reason, we also determined the concentration of FFA hydroperoxides in both groups.
Direct measurement of lipid hydroperoxides has only become possible with the advent of advanced HPLC technology, which enabled Yamamoto et al. (29) to develop an isoluminol-based, chemiluminescent assay for the determination of individual lipid hydroperoxides. Despite the greater sensitivity and specificity of this assay, no evidence of circulating lipid hydroperoxides was detected in control subjects. A similar observation was made by Holley and Slater (30) . No evidence of circulating lipid hydroperoxides was found in 66% of the C F patients studied. The range of lipid hydroperoxides in the remaining patients varied considerably, with a 15-fold difference being observed between the lowest and the highest concentrations. There was no correlation between TBA-reactive substances and lipid hydroperoxides, which is not altogether surprising considering the lack of specificity of the TBA test and the fact that the HPLC assay specifically measures oxidized FFA.
Lipids are not the only target for free radical attack in vivo; it is known that various amino acid residues including histidine, tryptophan, cysteine, proline, arginine, and lysine are particularly susceptible to oxidative attack (31) . Oxidative damage to several of these residues as well as to the peptide backbone of proteins can lead to the formation of carbonyl products. We found no significant difference in markers of protein oxidation between controls and patients with CF (Fig. 2) ; however, a wider distribution in values was observed in the C F patients. Although the group as a whole showed no evidence of protein peroxidation, it does appear that some individuals were more susceptible, with seven patients having values greater than 2 nmollmg protein. There was no correlation between markers of oxidative damage to lipids and protein carbonyls, which suggests that different mechanisms of damage are in operation or that the susceptibility to damage and breakdown of the subsequent metabolites differs between proteins and lipids.
We had assumed that the degree of oxidative damage would be reflected in the decreased antioxidant concentrations previously reported in CF. However, the concentrations of four main plasma antioxidants in the CF patients were all within reported normal ranges. This is not surprising, because all the patients were receiving vitamin supplements and the pancreatic enzyme Creon (Reid-Rowell, Marietta, GA). The program of dietary management and nutrient supplementation instituted at Southampton General Hospital has stabilized the plasma concentrations of vitamin E in C F patients as reported previously (6) .
Both intracellular and extracellular antioxidant compartments come into contact with free radicals produced by activated neutrophils in the lung of the CF patient. In particular, the RTLF may be important in this respect. Although some information is available about the antioxidant capacity of this fluid (32, 33) , sampling problems have greatly hindered elucidation of the precise chemical composition of RTLF. By contrast, the antioxidant defenses of human plasma have been well characterized and are seen by many as an acceptable model system in which to study events that are relevant to reactions occurring in RTLF (34, 35) . Indeed, it is hoped that plasma antioxidant capacity is representative in part of the antioxidant capacity of RTLF. It remains to be seen, however, how relevant such measurements in plasma are to the event that is taking place on the outer surface of the lung.
The role of the immune system in causing lung damage in patients with CF is now generally recognized (36) . Much attention has focused on the effects of elastase secreted by neutrophils in mediating this damage (8, 37 ), yet the direct contributory role of oxidant species has been largely ignored. A recent study has shown that, in addition to neutrophils as a source of free radicals, two secretory products of Pseudomonas aeruginosa, the most commonly found pathogenic bacterium in CF, are capable of damaging local tissues through the generation of hydroxyl radicals (38). Thus, the degree of colonization by bacterial strains and the severity of the lung infection will have an important bearing on the production of free radicals and consequently on the resulting damage. However, although it has been established that P. aeruginosa is an important stimulus for lower respiratory tract inflammation in CF, a recent study has shown that the burden of pathogens in bronchoalveolar lavage fluid does not appear to correlate with the degree of inflammation observed (39).
For an effective immune response to take place, the role of activated neutrophils in combating infection must outweigh any pulmonary damage inflicted by their excessive production of oxidizing species. Similarly, antioxidant therapy must attempt to prevent the latter without compromising the host's response to infection. A number of studies have investigated the effects of excess supplementation on immunologic status concentrating on vitamins C, E, and A (40-42). No detrimental effects of elevated vitamin supplementation on the immune system have been shown, and in fact mitogen response may be enhanced. Therefore, provision of a cocktail of antioxidants containing vitamin E, vitamin C, and possibly uric acid capable of elevating plasma antioxidants to the top of normal reported ranges while not unduly affecting the immune system may diminish oxidative lung damage. Caution should, however, be exercised with vitamin C supplementation, because vitamin C can act as a prooxidant in the presence of free iron. This may not be a problem in CF patients, because bacterial siderophores produced by P. aeruginosa bind most of the free iron available in the airway lining fluid (43).
The results of this study provide evidence of increased lipid peroxidation in patients with CF and show that certain individuals may be more susceptible to oxidative damage to both lipids and proteins even in the presence of normal concentrations of the main plasma antioxidants. Furthermore, the results confirm the validity of the current belief in the management of CF that decreasing the inflammatory response may prevent excessive damage (10) . However, increased antioxidant supplementation on an individual basis may also play a part in clinical management, inasmuch as evidence of damage was observed even in the presence of normal plasma antioxidant concentrations.
